VGA039 : Vega Therapeutics begins clinical trial of Von Willebrand disease candidate
Vega Therapeutics has launched the clinical trial program for VGA039, an investigational antibody therapy for Von Willebrand disease (VWD), a bleeding disorder in which the blood does not properly clot. The California-based clinical-stage biotech company has dosed the first subject in a phase 1 study labeled NCT05776069 with VGA039. NCT05776069 is a multinational clinical trial […]